Frontlight ResearchEarly access
Type 2 diabetes trials in South Korea
55 of 66 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 3Not yet taking people in South KoreaA Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes
- Where
- Ansan-si, Busan, Guri-si, Gwangju, Gyeongsan-si, Junggu, Namdong-gu, Seogu, Seongnam, Seongnam-si, Seoul
- Age
- 18 years and over
- People
- 2,115 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07881432 · EU 2026-526047-34-00 - Phase 3Not yet taking people in South KoreaA Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk
- Where
- Bucheon-si, Busan, Guri-si, Gwangju, Gyeongsan-si, Incheon, Seogu, Seongnam, Seoul, Ulsan, Wŏnju
- Age
- 45 years to 64 years
- People
- 3,000 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07900633 · EU 2026-525919-14-00 - Phase 3Taking peopleEASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
- Where
- Ansan-si, Bucheon-si, Busan, Daejeon, Daejoen, Gwangju, Incheon, Seongnam, Seoul, Suwon, Wŏnju
- Age
- 18 years and over
- People
- 11,800 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07064473 · EU 2025-521188-11-00 - Phase 3Not yet taking people in South KoreaA Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Treated With Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or Both
- Where
- Bucheon-si, Gwangju, Seoul, Wŏnju
- Age
- 18 years and over
- People
- 450 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07931547 · EU 2026-525471-13-00 - Phase 3Not yet taking people in South KoreaA Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both
- Where
- Ansan-si, Busan, Daegu, Seoul, Ulsan, Yongin-si
- Age
- 18 years and over
- People
- 1,060 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07931599 · EU 2026-525474-20-00 - Phase 3Taking peopleA Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
- Where
- Daegu, Daejeon, Gwangju, Gyeonggi-do, Incheon, Seongnam-si, Seoul
- Age
- 18 years and over
- People
- 2,000 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07351045 · EU 2025-523104-71-00 - Phase 3Taking peopleA Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Where
- Daejeon, Gangwon-do, Gwangju, Gyeonggi-do, Seongnam-si, Seoul
- Age
- 18 years and over
- People
- 1,600 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07351058 · EU 2025-523106-32-00 - Phase 3Taking peopleA Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
- Where
- Anyang-si, Daejeon, Incheon, Seoul, Yangsan
- Age
- 18 years and over
- People
- 954 worldwide
- Run by
- Pfizer
See details and how to joinNCT07595549 · EU 2026-525318-75-00 - Phase 3Not yet taking people in South KoreaA Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
- Where
- Bucheon-si, Deagu, Junggu, Seongnam, Seoul
- Age
- 10 years to 17 years
- People
- 170 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07668336 · EU 2025-524811-35-00 - Phase 3Taking peopleA Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- Where
- Ansan-si, Guri-si, Gwangju, Seongnam, Seoul
- Age
- 18 years and over
- People
- 1,035 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07282600 · EU 2025-523658-15-00 - Phase 3Not yet taking people in South KoreaA Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
- Where
- Ansan-si, Gwangju, Seongnam, Seoul
- Age
- 18 years and over
- People
- 1,000 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07881458 · EU 2026-527230-31-00 - Phase 3Taking peopleA Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
- Where
- Busan, Goyang-si, Guri-si, Gwangju, Gyeonggi-do, Seoul, Suwon, Yangsan
- Age
- 18 years and over
- People
- 2,000 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07662109 · EU 2025-523941-81-00 - Phase 3Taking peopleA Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Where
- Anyang, Bucheon-si, Daegu, Seoul, Yangsan
- Age
- 18 years and over
- People
- 2,500 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07784725 · EU 2025-523379-41-00 - Phase 3Not yet taking people in South KoreaA Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Where
- Busan, Daegu, Daejeon, Incheon, Seoul, Suwon
- Age
- 18 years and over
- People
- 1,500 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07784270 - Phase 3Taking peopleA Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
- Where
- Busan, Changwon-si, Daegu, Daejeon, Guri-si, Incheon, Seoul
- Age
- 18 years and over
- People
- 1,200 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07662213 · EU 2025-523933-24-00 - No phaseNot yet taking people in South KoreaContinuous Glucose Monitoring and Dietary Self-Management in Adults in Namwon
- Where
- Namwon
- Age
- 40 years and over
- People
- 860
- Run by
- Ji-Yeob Choi
See details and how to joinNCT07890740 - Phase 3Taking peopleA Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy
- Where
- Seoul
- Age
- 19 years and over
- People
- 276 worldwide
- Run by
- Boryung Pharmaceutical Co., Ltd
See details and how to joinNCT06220773 - Phase 3Taking peopleA Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
- Where
- Busan, Daegu, Goyang-si, Gyeonggi-do, Incheon, Jongno-gu, Seoul, Suwon
- Age
- 18 years and over
- People
- 4,500 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07667803 - Phase 2Not yet taking people in South KoreaA Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes
- Where
- Gwangju, Seoul
- Age
- 18 years to 75 years
- People
- 300 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07668388 · EU 2026-525465-42-00 - Phase 3Taking peopleA Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- Where
- Namdong-gu, Seogu, Seongnam, Seoul, Yangsan
- Age
- 18 years and over
- People
- 1,980 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07321886 · EU 2025-523657-34-00 - Phase 2Taking peopleA Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes
- Where
- Ansan-si, Seoul, Yangsan
- Age
- 18 years to 75 years
- People
- 270 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07415954 · EU 2025-523260-20-00 - Phase 3Not yet taking people in South KoreaA Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus
- Where
- Jongno-gu, Seongnam-si, Seoul
- Age
- 18 years and over
- People
- 800 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07662044 · EU 2025-523936-37-00 - No phaseTaking peopleSurgical TreAtment for Obesity Related Disease and Onco-Metabolic Surgery
- Where
- Seoul
- Age
- 20 years to 69 years
- People
- 120
- Run by
- Korea University Anam Hospital
See details and how to joinNCT04284943 - Phase 3Not yet taking people in South KoreaA Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin
- Where
- Bucheon-si, Gyeonggi-do, Jongno-gu, Junggu, Seoul
- Age
- 18 years and over
- People
- 600 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07664553 · EU 2025-523935-20-00 - Phase 4Taking peopleCilostazol and Aspirin for Cardiovascular Event Prevention in Patients With Type 2 Diabetes
- Where
- Seongnam-si
- Age
- 19 years and over
- People
- 1,200
- Run by
- Seoul National University Bundang Hospital
See details and how to joinNCT07719894